Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.
Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice
It is demonstrated for the first time that pharmacological DPP4 inhibition by evogliptin directly causes fat loss in established obese mice, providing insight into the regulation of energy storage in WAT caused by DPP 4 inhibition.
PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
PAR-1622 is a selective peroxisome proliferator-activated receptor γ partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention
The results suggest that PAR-1622 is a selective partial activator of PPARγ and has excellent antihyperglycemic activities and a broad safety profile for fluid retention.
Myeloid Sirtuin 6 Deficiency Causes Insulin Resistance in High-Fat Diet–Fed Mice by Eliciting Macrophage Polarization Toward an M1 Phenotype
It is concluded that Sirt6 in macrophages is required for the prevention of obesity-associated tissue inflammation and insulin resistance.
Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control
Results suggest that central CB1 receptors mediate anorectic response ofCB1-receptor antagonists and peripheral modulations, including SREBP-1 expression, are not major mechanisms in the antiobesity effects of CB1- receptor antagonists.
Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
Compound 18, one of the derivatives with an oxime ether linker, was found to selectively transactivate PPARgamma and lower blood glucose in db/ db mice more than muraglitazar after oral treatment for 11 days.
Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models
It is suggested that evogliptin treatment ameliorates fatty liver by increasing insulin sensitivity and suppressing lipogenesis and reduction in plasma non-esterified fatty acids supported the improvement of insulin resistance by evoglisptin treatment.
PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.